On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 6, 2005, Pages 1174-1179

  Lijnen, H R ^a   Alessi, M C ^b   Van Hoef, B ^a   Collen, D ^a   Juhan Vague, I ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b TIMONE HOSPITAL   (France)

Author keywords

Adipose tissue; glucose tolerance; insulin resistance; obesity; plasminogen activator inhibitor; transgenic mice

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; ACETIC ACID DERIVATIVE; INDOLE DERIVATIVE; INDOLEACETIC ACID DERIVATIVE; INSULIN; TIPLAXTININ;

ADIPOSE TISSUE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; FOOD; GENOTYPE; GLUCOSE TOLERANCE TEST; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; BLOOD; BODY COMPOSITION; C57BL MOUSE; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PHYSIOLOGY;

ACETIC ACIDS; ADIPOSE TISSUE; ANIMALS; BODY COMPOSITION; BODY WEIGHT; INDOLEACETIC ACIDS; INDOLES; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 24944474033     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01390.x     Document Type: Article

References (30)

1. Lijnen HR. Pleioptropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
2. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-3.
3. Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2: 568-82.
4. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7.
5. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, Verdier M, Geel O, Juhan-Vague I. Plasminogen activator inhibitor 1, transforming growth factor-beta 1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374-80.
6. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-62.
7. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995; 92: 1779-85.
8. Pannacciulli N, De Mitrio V, Marino R, Giorgino R, De Pergola G. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects. Obes Res 2002; 10: 717-25.
9. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 1131-7.
10. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and on metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 2000; 20: 1150-4.
11. Lijnen HR, Maquoi E, Morange P, Voros G, Van Hoef B, Kopp F, Collen D, Juhan-Vague I, Alessi MC. Nutritionally induced obesity is attenuated in trangenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23: 78-84.
12. Eren M, Su M, Atkinson J, King L, Declerck P, Vaughan DE. Phenotypic derangements associated with overexpression of plasminogen activator inhibitor-1 (PAI-1) in transgenic mice. Arterioscler Thromb Vasc Biol 2001; 21: 695 (Abstract 20).
13. Schafer K, Fujisawa K, Konstantinides S, Loskutoff J. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15: 1840-2.
14. Ma L-J, Mao S-L, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-46.
15. Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, Crandall DL. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem 2004; 47: 3491-4.
16. Crandall DL, Elokdah H, Di L, Hennan JK, Gorlatova NV, Lawrence DA. Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy. J Thromb Haemost 2004; 2: 1422-8.
17. Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-84.
18. Laitinen L. Griffonia Simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem J 1987; 19: 225-34.
19. Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-activated mice. Thromb Haemost 1995; 74: 1305-9.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatic model assessment: insulin resistance and β-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9
21. Carvalho CR, Brenelli SL, Silva AC, Nunes AL, Velloso LA, Saad MJ. Effect of aging on insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of rats. Endocrinology 1996; 137: 151-9.
22. Fink R, Wallace P, Olefsky JM. Effect of aging on glucose-mediated glucose disposal and glucose transport. J Clin Invest 1986; 77: 2034-41.
23. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Noel A, Foidart JM. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002; 16: 147-54.
24. Eren M, Cleaves L, Walker E, Covington J, Painter C, Atkinson J, Elokdah H, Crandall DL, Vaughan DE. Inhibition of PAI-1 Activity Reduces Angiotensin II Induced Aortic Atherosclerosis and Aneurysm in ApoE Deficient Mice. Orlando, FL, USA: American Heart Association Meetings, 2003.
25. Liu J, Antrim TM, Elokdah H, Hennan JK, Crandall DL, Fay WP. Inhibition of plasminogen activator inhibitor-1 protects against atherosclerosis progression in apolipoprotein E-deficient mice. Blood 2003; 102: Abstract.
26. Morange PE, Aubert J, Peiretti F, Lijnen HR, Vague P, Verdier M, Negrel R, Juhan-Vague I, Alessi MC. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 1999; 48: 890-895
27. Lopez-Alemany R, Redondo JM, Nagamine Y, Munoz-Canoves P. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur J Biochem 2003; 270: 814-21.
28. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 365-71.
29. Miles PDG, Barak Y, Evans RM, Olefsky JM. Effect of heterozygous PPARγ deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding. Am J Physiol Endocrinol Metab 2003; 284: E618-26.
30. Muurling M, Mensink RP, Pijl H, Romijn JA, Havekes LM, Voshol PJ. Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice. Metabolism 2003; 52: 1078-83.